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Pemphigus and Pemphigoid Meeting in
Munich, September 2016
Enno Schmidt1,2,24, Volker Spindler3,24, Ru¨diger Eming4,24, Masayuki Amagai5, Frank Antonicelli6,
John F. Baines7, Meriem Belheouane7, Philippe Bernard6, Luca Borradori8, Marzia Caproni9,
Giovanni Di Zenzo10, Sergei Grando11, Karen Harman12, Marcel F. Jonkman13, Hiroshi Koga14,
Ralf J. Ludwig2, Andrew P. Kowalczyk15, Eliane J. Mu¨ller8,16, Wataru Nishie17, Hendri Pas13,
Aimee S. Payne18, Christian D. Sadik1, Allan Seppa¨nen19, Jane Setterfield20, Hiroshi Shimizu17,
Animesh A. Sinha21, Eli Sprecher22, Michael Sticherling23, Hideyuki Ujiie17, Detlef Zillikens1,24,
Michael Hertl4,24 and Jens Waschke3,24Autoimmune blistering diseases are a heterogeneous group of about a dozen complex disorders that are
characterized by intraepidermal (pemphigus) and subepidermal blistering (pemphigoid diseases and dermatitis
herpetiformis). The Pathogenesis of Pemphigus and Pemphigoid Meeting, organized by the Departments of
Dermatology in Lu¨beck and Marburg and the Institute of Anatomy and Cell Biology, Munich, was held in
September 2016 in Munich. The meeting brought together basic scientists and clinicians from all continents
dedicating their work to autoimmune blistering diseases. Considerable advances have been made in describing
incidences and prevalences of these diseases and linking comorbidities with autoantibody reactivities and
clinical variants, for example, dipeptidyl peptidase-IV inhibitor-associated noninflammatory bullous pemphi-
goid. Although new entities are still being described, diagnosis of most autoimmune blistering diseases can
now be achieved using standardized and widely available serological test systems. Various experimental mouse
models of pemphigus and pemphigoid disease are increasingly being used to understand mechanisms of
central and peripheral tolerance and to evaluate more specific treatment approaches for these disorders, such
as molecules that target autoreactive T and B cells and anti-inflammatory mediators, that is, dimethyl fumarate,
phosphodiesterase 4, and leukotriene B4 inhibitors in pemphigoid disorders, and chimeric antigen receptor T
cells in pemphigus. Very recent experimental data about the immunopathology and the determinants of
autoantibody formation and keratinocyte susceptibility in pemphigus were discussed. With regard to cellular
mechanisms leading to the loss of cell-cell adhesion, new ideas were shared in the field of signal transduction.
Major steps were taken to put the various partly contradictory and controversial findings about the effects of
pemphigus autoantibodies and other inflammatory mediators into perspective and broaden our view of the
complex pathophysiology of this disease. Finally, two investigator-initiated multicenter trials highlighted
doxycycline and dapsone as valuable medications in the treatment of bullous pemphigoid.
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1200INTRODUCTION
After successful international meetings
on autoimmune blistering diseases in
Salzburg (1998), Otsu (2008), and
Lu¨beck (2013), we met in Munich
September 5e7, 2016 to discuss recent
advances in the understanding of these
complex prototypic autoantibody-
mediated disorders (Figure 1). Plenary
lectures were given by the authors
flanked by oral presentations selected
from the 66 abstracts that were dis-
cussed in a poster session. The first day
was dedicated to all aspects of the
different pemphigoid diseases, and the
second day focused on the pathogen-
esis of pemphigus disorders.
PEMPHIGOID DISORDERS
Epidemiology
Although the incidences of autoim-
mune blistering disease (AIBD) have
been studied in a variety of different
populations, data about the prevalence
of these disorders are sparse. Franziska
Hu¨bner of Lu¨beck, Germany, collabo-
rated with the largest German health
insurance company, the Techniker
Krankenkasse. Based on coding from
the International Classification of Dis-
ease, 10th revision (World Health
Organization, 1990) she calculated a
total number of 40,400 patients (0.05%
of a population of 80,925,000) with
autoimmune blistering diseases in
Germany in 2014 (Hubner et al., 2016).
Bullous pemphigoid (BP), pemphigus
vulgaris (PV), and mucous membrane
pemphigoid (MMP) were identified as
the most prevalent disorders with
adjusted prevalences of 259.3, 94.8,
and 24.56 per million inhabitants,
respectively (Hubner et al., 2016).
By far the most frequent AIBD, BP is
known to be highly associated with old
age, distinct drugs, and several neuro-
logic and psychiatric diseases, collec-
tively affecting 30e50% of BP patients.
This last observation is particularly
intriguing, because BP180 (type XVII
collagen), the main target antigen in BP,
is expressed in different parts of the
central nervous system such as the
hippocampus, thalamus, midbrain, and
basal forebrain. In line with this, Laura
Huilaja of Oulu, Finland, reported that
serum levels of anti-BP180 antibodies
correlate with more severe dementia
and Alzheimer disease, indicating
a potential relation between theJournal of Investigative Dermatology (2017), Volumautoimmune skin disease and the cen-
tral nervous pathology (Kokkonen et al.,
2017). Drug intake as another potential
trigger of BP was addressed by Wataru
Nishie. Based on the increasing number
of dipeptidyl peptidase-IV inhibitor
(gliptin inhibitor for diabetic control)e
associated BP, his group observed,
using a full-length BP180 ELISA, that
dipeptidyl peptidase-IV inhibitore
associated BP tends to show a non-
inflammatory phenotype and that
autoantibodies are more likely to target
epitopes on the BP180 ectodomain
outside NC16A (Izumi et al., 2016).
These data further support previous
observations that not all BP patients
generate antibodies against the immu-
nodominant NC16A domain of BP180
and that several clinical BP variants
exist in addition to the two classical
phenotypes, that is, tense blisters and
erosions or urticarial plaques and
erythema.
Skin microbiota have recently been
highlighted as related to disease
expression in a variety of inflammatory
disorders. Meriem Belheouane pre-
sented unpublished work on the role of
skin microbiota in modulating BP sus-
ceptibility. Using both a human cohort
and experimental BP in adult mice, she
found that the composition of skin
microbiota is associated with disease
severity, which supports a role of the
skin microbiota in the onset and
development of BP.
Diagnosis
Diagnosis of AIBDs is based on three
columns: clinical presentation, direct
immunofluorescence microscopy, and
detection of serum autoantibodies.
Although direct immunofluorescence
microscopy can still be regarded as the
diagnostic criterion standard, in many
patients diagnosis can be made by
serological analyses and the clinical
picture alone. In pemphigoid diseases,
immunoglobulin deposition at the
dermal-epidermal junction is not
entirely linear but slightly undulated.
Two patterns can be observed by direct
immunofluorescence microscopy: the
u-serrated pattern, with arches closed at
the bottom unique to autoimmunity
against type VII collagen (epidermolysis
bullosa acquisita [EBA] and bullous
systemic lupus erythematosus), and the
n-serrated pattern, with arches closed ate 137the top. The n-serrated pattern is seen in
all other pemphigoid disorders. Pattern
analysis is particularly valuable in EBA
patients because in this group, serum
autoantibodies can be detected in only
about half of patients. Although the
concept of a pattern diagnostic was
developed about a decade ago, it still
needs to spread widely in the routine
diagnostic workup of AIBDs.
Serological diagnosis of AIBDs has
been a rapidly expanding field over the
last years. Gabi Ommen of Lu¨beck,
Germany, introduced a previously
undescribed multivariant ELISA that
compiled six recombinant target anti-
gens, that is, desmoglein 1, desmoglein
3, envoplakin, BP180, BP230, and type
VII collagen. In two prospective studies,
this ELISA allowed the one-step sero-
logical diagnosis of 95% of pemphigus
and 71% of pemphigoid diseases and
will further facilitate the diagnosis of
AIBDs (Van Beek et al., 2017). Another
diagnostic approach was chosen by
Jane Setterfield analyzing saliva in pa-
tients with MMP. With a BP180 NC16A
ELISA, reactivity was seen in 45% of
MMP patients’ saliva compared with
52% in serum. In 64 MMP patients,
additional use of saliva increased
detection of IgG and/or IgA to BP180
NC16A to 67%, representing a 30%
increase (Ali et al., 2016).
Treatment
On behalf of the UK Dermatology
Clinical Trials Network in collaboration
with seven German centers, Karen
Harman presented the results of the
BLISTER trial. This prospective
controlled multicenter trial showed that
initiation of treatment with doxycycline
at 200 mg/day was noninferior in terms
of blister control at 6 weeks and supe-
rior in terms of number of severe
treatment-related events by 52 weeks
compared with tapering doses of pred-
nisolone at 0.5 mg/kg body weight/day.
This pragmatic trial suggests that for BP
patients in whom topical treatment is
not possible, a policy of starting treat-
ment with oral doxycycline produces
acceptable blister control in the short
term and better long-term safety than
conventional treatment with oral pred-
nisolone (Williams et al., 2017).
Another investigator-initiated multi-
center prospective controlled trial in BP
investigated the efficacy and safety of
Figure 1. Participants of the Pemphigus and Pemphigoid Pathogenesis Meeting, Munich, September 2016.
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combination with tapering doses of
prednisolone 0.5 mg/kg/day. Dapsone
appeared to be associated with a lower
cumulative prednisolone dose, sug-
gesting dapsone as a corticosteroid-
sparing agent in BP. Although a
gluten-free diet initially in combination
with dapsone is standard in the treat-
ment of dermatitis herpetiformis, Mar-
zia Caproni described that even
cutaneous manifestations of nonceliac
gluten sensitivity including itching,
eczematoid and psoriasiform lesions,
and C3 deposits at the dermal-
epidermal junction may rapidly
resolve with a gluten-free diet
(Bonciolini et al., 2015).
Pathophysiology
IL-17 and IL-17erelated cytokines are
currently the focus of research projects
in several inflammatory diseases, also
because of the potential application of
antieIL-17 therapy. Frank Antonicelli
and colleagues identified neutrophils as
a major source of IL-17 and related
cytokines such as IL-22 and IL-23,
being released in the serum and blister
fluids of BP patients. This inflammatory
network enhances MMP-9 secretion
and CXCL10 expression from several
leukocyte cell types and may lead to a
feedback loop and the perpetuation of
the autoinflammatory process (Riani
et al., 2016). In line with this,
sustained or enhanced serum levels of
IL-17, IL-23, and CXCL10 were associ-
ated with relapses in BP (Plee et al.,
2015). Another important aspect of BP
pathophysiology, complement activa-
tion, was addressed by Hideyuki Ujiie.He showed that both monoclonal hu-
man IgG4 to BP180, which lacks
complement activation ability, and
IgGs from patients with BP can induce
skin fragility in wild-type and
complement-deficient mice, respec-
tively. These data indicate that
complement-independent pathways
play an important role in blister for-
mation of BP.
The quest for more specific anti-
inflammatory regimens was driving the
work by Ralf Ludwig, who made use of
in vitro and in vivo model systems that
reflected major pathophysiological as-
pects of EBA. Dimethyl fumarate was
identified to be effective in experi-
mental EBA by inhibiting neutrophil
functions (Muller et al., 2016). Licensed
for the treatment of psoriasis and mul-
tiple sclerosis, dimethyl fumarate will
soon be evaluated in an investigator-
initiated prospective controlled trial in
patients with BP. Hiroshi Koga used a
similar approach and showed that
phosphodiesterase 4 inhibition signifi-
cantly reduces the pathogenic effect of
anti-type VII collagen IgG (Koga et al.,
2016). Studies by Christian Sadik pro-
vided evidence that eicosanoids play a
critical role in neutrophil homing into
the skin and skin inflammation in
response to binding of anti-type VII
collagen antibodies at the dermal-
epidermal junction (Sezin et al.,
2017). Markus Niebuhr of Lu¨beck,
Germany, using the immunization-
induced EBA mouse model, performed
T-cell repertoire analyses and proposed
that CD4-positive T cells are not only
instrumental in providing B-cell help
for Ig class switching but also inexpressing the proinflammatory cyto-
kine IFN-g in the skin in an
autoantigen-driven manner. For a
detailed study of autoantibody binding
and neutrophil extravasation, Jennifer
Klo¨pper of Lu¨beck, Germany used
fluorescent-labeled anti-type VII
collagen IgG and enhanced green
fluorescent protein transgenic mice
under the lysozyme M promotor in
experimental murine EBA by multi-
photon microscopy.
A thus far unreported mouse model
of anti-laminin 332 MMP that reflected
major clinical, histopathological, and
immunopathological characteristics of
the human disease was introduced by
Eva Heppe of Lu¨beck, Germany. In this
model, ocular, oral, and pharyngeal
lesions predominate, and lesions for-
mation was completely dependent on




There is general agreement that T
helper cells are critically involved in
regulating the formation of autoanti-
bodies in the pathogenesis of
pemphigus. Masayuki Amagai pre-
sented his view of peripheral tolerance
mechanisms down-regulating Dsg3-
specific CD4 T cells in an active
disease mouse model for PV. The
model was generated by adoptive
transfer of peripheral lymphocytes from
desmoglein (Dsg) 3-deficient (e/e) mice
to Rag2e/e immunodeficient mice,
because Dsg3-reactive T and B lym-
phocytes are not present in wild-type
mice that express Dsg3. Dsg3-specificwww.jidonline.org 1201
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specific TCR transgenic mice were
generated. A yet unpublished model to
analyze peripheral tolerance of Dsg3-
specific T cells was introduced by
bone marrow transfer of Dsg3-specific
TCR transgenic mice to recipient mice
with thymus transplantation from
Dsg3e/e and wild-type mice. In this
context, the importance of the periph-
eral tolerance model for the develop-
ment of a future antigen-specific
therapeutic strategy was discussed.
The current concept of T-cell
involvement in PV from the human
angle was presented by Ru¨diger Eming,
with a translational approach using a
previously established preclinical HLA
class II transgenic PV mouse model.
Activation of autoreactive T cells
responsive to the PV autoantigens, Dsg
1 and 3, in the context of HLA-
DRB1*04:02, led, via B-cell help, to
the induction of IgG autoantibodies
and, eventually, loss of epidermal
adhesion. Using this model, he further
showed that T regulatory cells down-
regulate autoreactive T cells and may
thus be exploited therapeutically
(Schmidt et al., 2016). This preclinical
model is currently used to develop a
Dsg3 peptide-based, T-celletargeted
immunotherapy of PV. Robert Pollmann
of Marburg, Germany, presented evi-
dence that IL-21eproducing T helper
type 17 cells and T follicular helper
cells are augmented in PV (Hennerici
et al., 2016).
Aimee Payne gave insights into the
lineage relationships of the IgG1-,
IgG4-, IgA1-, and IgA2-specific B-cell
repertoires in pemphigus using deep
sequencing approaches paired with
antibody phage display to identify Dsg-
reactive lineages. Whereas IgA1 and
IgA2 B-cell repertoires showed signifi-
cant clonal overlap and shared muta-
tions suggestive of sequential class
switch from anti-Dsg IgA1 to IgA2,
IgG4 B cells showed infrequent clonal
overlap with other isotypes, with only
one example of anti-Dsg IgG1 to IgG4
sequential class switch. These data
indicate that anti-Dsg IgG1, IgG4,
and IgA B-cell repertoires largely
evolve independently from one another
or arise from common precursors
but through divergent pathways of
somatic mutation. Christoph Ellebrecht
of Philadelphia, Pennsylvania, USA,Journal of Investigative Dermatology (2017), Volumpresented an exciting approach to
treating autoimmunity in pemphigus
using chimeric immunoreceptors
adapted from those that have been used
to successfully treat B-cell leukemias.
Using the autoantigen Dsg3 as the
extracellular domain of a “chimeric
autoantibody receptor”, he showed
that Dsg3 chimeric autoantibody
receptor T cells specifically kill anti-
Dsg3 B cells in a PV mouse model,
even in the presence of soluble anti-
Dsg3 antibodies, thus providing a
potent and feasible strategy for targeted
B-cell depletion in pemphigus, which
could potentially be extended to
any autoantibody-mediated disease
(Ellebrecht et al., 2016).
Role of anti-desmoglein versus
noneanti-desmoglein antibodies and
other factors
In the session on different antibodies
and nonantibody factors in skin blis-
tering, Jens Waschke revisited data
showing that immunoadsorption of an-
tibodies targeting Dsg1 and Dsg3
abrogated pathogenic effects of pa-
tients’ IgG. Because, on the other hand,
Dsg3-specific autoantibodies such as
AK23 induce loss of keratinocyte
cohesion and Dsg3-deficient mice
show pemphigus-like lesions in
epidermis and conjunctiva, these data
support the notion that anti-Dsg anti-
bodies are pathogenic. In line with this,
Stephanie Goletz of Lu¨beck, Germany,
presented unpublished data on Dsg1-
and Dsg3-specific immunoadsorption
in the neonatal pemphigus mouse
model. Because targeting Dsg3 was
paralleled by activation of p38
mitogen-activated protein kinase, the
inhibition of which reduced loss of
cohesion, Jens Waschke proposed that
desmogleins form signaling hubs regu-
lating keratinocyte adhesion and
migration (Rotzer et al., 2015) and that
signaling patterns may correlate with
clinical phenotypes. A role for p38
mitogen-activated protein kinase in the
pathogenesis of pemphigus foliaceus
was also shown in unpublished data
from Kenji Yoshida of Tokyo, Japan,
indicating that Dsg1 clustering is
mediated by polyclonal IgG.
The role of autoantibodies directed
against other antigens was reviewed by
Sergei Grando. He suggested that anti-
bodies targeting other cell-membranee 137and intracellular antigens, such as
mitochondrial proteins, synergize with
anti-desmoglein antibodies to cause
pemphigus. In line with this, Animesh
Sinha reported recent data indicating
IgG reactivity against muscarinic
acetylcholine receptors and thyroid
peroxidase, the expression of which
was driven by HLA (Sajda et al., 2016).
Finally, Carlo Pincelli of Modena, Italy
presented that PV-IgGeinduced Dsg3
cleavage is inhibited by anti-FasL anti-
bodies, indicating a role for FasL in
pemphigus.
Mechanisms causing blister formation
in pemphigus
Marcel Jonkman reported that desmo-
somes become reduced in size and
number in PVand PF patients’ skin biopsy
specimens. Depletion of desmogleins
begins in the lower epidermis, whereas
the IgG-dependent clustering of Dsg
molecules is not required for acantholysis.
Ena Sokol from the same group presented
unpublished work on morphological
changes in keratinocytes as a result of
autoantibody exposure, which may be
required for desmoglein internalization.
Andrew Kowalczyk showed unpublished
data on the mechanisms of lipid raft-
mediated turnover of desmosomal mole-
cules. The close relationship of lipid rafts
anddesmosomeswas further underscored
in a talk by Antje Banning of Giessen,
Germany, who showed that reduced
levels of the lipid raft markers flotillin-1
and -2 result in altered Dsg3 distribution
and loss of cell cohesion (Vollner et al.,
2016). Volker Spindler showed that
modulationof signaling canovercome the
effects of inhibitory autoantibodies
(Vielmuth et al., 2015) and suggested a
scenario in which altered keratin filament
distribution in response to signaling may
compromise desmosome function. In line
with this, modulation of signaling path-
ways mediated by extra-desmosomal
Dsg3 receptors was suggested as a thera-
peutic approach by Eliane Mu¨ller in her
talk summarizing the role of different
published and unpublished signaling
molecules in pemphigus (Luyet et al.,
2015). Eli Sprecher outlined that PV pa-
tients can carry a variant of the ST18 gene,
which enhances susceptibility of kerati-
nocytes to the deleterious effects of auto-
antibodies, indicating that autoantibody
pathogenicity may be genetically modu-
lated (Vodo et al., 2016).
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consensus session moderated by Carien
Niessen of Cologne, Germany, in
which the main controversies in the
pathogenesis of pemphigus were
addressed and discussed to reach a
conceptual framework that the scienti-
fic community largely agrees on. The
results of this session are planned to be
presented as a review on pemphigus
pathogenesis in the near future.
CONFLICT OF INTEREST
The authors state no conflict of interest.
REFERENCES
Ali S, Kelly C, Challacombe SJ, Donaldson AN,
Dart JK, Gleeson M, et al. Salivary IgA and IgG
antibodies to bullous pemphigoid 180 non-
collagenous domain 16a as diagnostic bio-
markers in mucous membrane pemphigoid. Br J
Dermatol 2016;174:1022e9.
Bonciolini V, Bianchi B, Del Bianco E, Verdelli A,
Caproni M. Cutaneous manifestations of non-
celiac gluten sensitivity: clinical histological
and immunopathological features. Nutrients
2015;7:7798e805.
Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X,
Cho MJ, et al. Reengineering chimeric antigen
receptor T cells for targeted therapy of autoim-
mune disease. Science 2016;353:179e84.
Hennerici T, Pollmann R, Schmidt T, Seipelt M,
Tackenberg B, Mobs C, et al. Increased fre-
quency of T follicular helper cells and elevated
interleukin-27 plasma levels in patients with
pemphigus. PLOS One 2016;11:e0148919.
Hubner F, Recke A, Zillikens D, Linder R,
Schmidt E. Prevalence and age distribution of
pemphigus and pemphigoid diseases in ger-
many. J Invest Dermatol 2016;136:2495e8.
Izumi K, Nishie W, Mai Y, Wada M, Natsuga K,
Ujiie H, et al. Autoantibody profile differenti-
ates between inflammatory and noninflamma-
tory bullous pemphigoid. J Invest Dermatol
2016;136:2201e10.Koga H, Recke A, Vidarsson G, Pas HH,
Jonkman MF, Hashimoto T, et al. PDE4 inhibi-
tion as potential treatment of epidermolysis
bullosa acquisita. J Invest Dermatol 2016;136:
2211e20.
Kokkonen N, Herukka SK, Huilaja L, Kokki M,
Koivisto AM, Hartikainen P, et al. Increased
levels of the bullous pemphigoid BP180 auto-
antibody are associated with more severe
dementia in Alzheimer’s disease. J Invest
Dermatol 2017;137:71e6.
Luyet C, Schulze K, Sayar BS, Howald D,
Muller EJ, Galichet A. Preclinical studies iden-
tify non-apoptotic low-level caspase-3 as ther-
apeutic target in pemphigus vulgaris. PLOS
One 2015;10:e0119809.
Muller S, Behnen M, Bieber K, Moller S,
Hellberg L, Witte M, et al. Dimethylfumarate
Impairs Neutrophil Functions. J Invest Dermatol
2016;136:117e26.
Plee J, Le Jan S, Giustiniani J, Barbe C, Joly P,
Bedane C, et al. Integrating longitudinal serum
IL-17 and IL-23 follow-up, along with autoanti-
bodies variation, contributes to predict bullous
pemphigoid outcome. Sci Rep 2015;5:18001.
Riani M, Le Jan S, Plee J, Durlach A, Le Naour R,
Haegeman G, et al. Bullous pemphigoid
outcome is associated with CXCL10-induced
matrix metalloproteinase 9 secretion from
monocytes and neutrophils but not lympho-
cytes [e-pub ahead of print]. J Allergy Clin
Immunol 2016; http://dx.doi.org/10.1016/j.
jaci.2016.08.012 (accessed 1 March 2017).
Rotzer V, Hartlieb E, Vielmuth F, Gliem M,
Spindler V, Waschke J. E-cadherin and Src
associate with extradesmosomal Dsg3 and
modulate desmosome assembly and adhesion.
Cell Mol Life Sci 2015;72:4885e97.
Sajda T, Hazelton J, Patel M, Seiffert-Sinha K,
Steinman L, Robinson W, et al. Multiplexed
autoantigen microarrays identify HLA as a key
driver of anti-desmoglein and -non-desmoglein
reactivities in pemphigus. Proc Natl Acad Sci
USA 2016;113:1859e64.
Schmidt T, Willenborg S, Hunig T, Deeg CA,
Sonderstrup G, Hertl M, et al. Induction
of T regulatory cells by the superagonisticanti-CD28 antibody D665 leads to
decreased pathogenic IgG autoantibodies
against desmoglein 3 in a HLA-transgenic
mouse model of pemphigus vulgaris. Exp
Dermatol 2016;25:293e8.
Sezin T, Krajewski M, Wutkowski A, Mousavi S,
Chakievska L, Bieber K, et al. The leukotriene
B4 and its receptor BLT1 act as critical drivers of
neutrophil recruitment in murine bullous
pemphigoid-like epidermolysis bullosa acquis-
ita [e-pub ahead of print]. J Invest Dermatol
2017. http://dx.doi.org/10.1016/j.jid.2016.12.
021 (accessed 1 March 2017).
Van Beek N, Da¨hnrich C, Johannsen N,
Lemcke S, Goletz S, Hu¨bner F, et al.
Prospective studies on the routine use of a
novel multivariant ELISA for the diagnosis of
autoimmune bullous diseases [e-pub ahead of
print]. J Am Acad Dermatol 2017. http://dx.
doi.org/10.1016/j.jaad.2016.11.002 (accessed
1 March 2017).
Vielmuth F, Waschke J, Spindler V. Loss of des-
moglein binding is not sufficient for keratino-
cyte dissociation in pemphigus. J Invest
Dermatol 2015;135:3068e77.
Vodo D, Sarig O, Geller S, Ben-Asher E,
Olender T, Bochner R, et al. Identification of a
functional risk variant for pemphigus vulgaris in
the ST18 gene. PLOS Genet 2016;12:
e1006008.
Vollner F, Ali J, Kurrle N, Exner Y, Eming R,
Hertl M, et al. Loss of flotillin expression results
in weakened desmosomal adhesion and
pemphigus vulgaris-like localisation of
desmoglein-3 in human keratinocytes. Sci Rep
2016;6:28820.
Williams HC, Wojnarowska F, Kirtschig G,
Mason J, Godec TR, Schmidt E, et al. Doxy-
cycline versus prednisolone as an initial
treatment strategy for bullous pemphigoid: a
pragmatic, non-inferiority, randomised
controlled trial [e-pub ahead of print] Lancet
2017; http://dx.doi.org/10.1016/S0140-
6736(17)30560-3 (accessed 6 March 2017).
World Health Organization. International classi-
fication of diseases and related health prob-
lems, 10th revision. Geneva, Switzerland:
World Health Organization; 1990.www.jidonline.org 1203
